<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02187900</url>
  </required_header>
  <id_info>
    <org_study_id>HNXY201401</org_study_id>
    <nct_id>NCT02187900</nct_id>
  </id_info>
  <brief_title>Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.</brief_title>
  <official_title>Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Multi-glycoside of Tripterygium Wilfordii
      HOOK. f. is effective and safe in the treatment of IgA nephropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary IgA nephropathy (IgAN) is the most common form of idiopathic glomerulonephritis
      throughout of the world. The disease is characterized by the predominant deposition of
      polymer Gal-deﬁcient IgA1 immune complex（pGd-IgA1-IC）in the glomeruli which leads to the
      proliferation of mesangial cells. Mycophenolate mofetil is reported to be useful in the
      treatment of IgAN in Chinese patients, but the price is expensive together with some adverse
      events. Tripterygium Wilfordii HOOK. f. is a traditional chinese medicine and is useful in
      the treatment of CKD, the purpose of this study is to determine whether Multi-glycoside of
      Tripterygium Wilfordii HOOK. f. is effective and safe in the treatment of IgA nephropathy
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients reaching remission</measure>
    <time_frame>one year</time_frame>
    <description>(i) complete remission was deﬁned as the absence of proteinuria (24-h urine protein &lt; 0.4 g/24 h), serum albumin &gt;35 g/L and Scr &lt; 1.24 mg/ dL; (ii) partial remission was deﬁned as a 24-h urine protein ≤ 3.5 g/24 h and a decline of &gt;50% of the baseline value with an Scr elevation of &lt;15% of the baseline value; (iii) no response was deﬁned as a 24-h urine protein &gt;3.5 g/24h, or a decline &lt; 50% of base- line value or increase and/or an Scr level &gt;50% of the baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal survival</measure>
    <time_frame>one year</time_frame>
    <description>Renal survival was estimated on the basis of a 50% increase in baseline serum creatinine concentration.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse event</measure>
    <time_frame>one year</time_frame>
    <description>liver function test result abnormalities;menstrual disturbance</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>TWH for the treatment of IgAN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions :The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMF for IgAN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MMF for the treatment of IgAN for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)</intervention_name>
    <description>The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.</description>
    <arm_group_label>TWH for the treatment of IgAN</arm_group_label>
    <other_name>Multi-glycoside of Tripterygium Wilfordii HOOK. f.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <description>Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months</description>
    <arm_group_label>MMF for IgAN</arm_group_label>
    <other_name>Mycophenolate mofetil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  urinary protein levels ≥1.0 g/24 h

          -  estimated glomerular filtration rate (eGFR) ≥30 ml·min-1·1.73 m-2body surface area by
             the MDRD formula (eGFR=194×age-0.287×serum creatinine

          -  1.094(×0.739, if female) (where sCr is the serum creatinine, dry chemistry method,
             mg/dl))

          -  peripheral blood white blood cell count ≥3000×109/L

          -  no other cause for tubulointerstitial lesions

          -  no history of immunomodulatory agent intake before renal biopsy

          -  no systemic infection

          -  age between 16 and 65 years

        Exclusion Criteria:

          -  severe infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenghua Zhou, MD</last_name>
    <role>Study Director</role>
    <affiliation>the second xiangya hospital of CSU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youming Peng, M.D</last_name>
    <phone>8615802604114</phone>
  </overall_contact>
  <location>
    <facility>
      <name>The second Xiangya Hospital of CSU</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liyu He , M.D</last_name>
      <phone>8615802604114</phone>
      <email>heliyu1124@126.com</email>
    </contact>
    <investigator>
      <last_name>Liyu He, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2014</study_first_submitted>
  <study_first_submitted_qc>July 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2014</study_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>Youming Peng</investigator_full_name>
    <investigator_title>Director of the Nephrology Institute</investigator_title>
  </responsible_party>
  <keyword>Tripterygium Wilfordii HOOK. f.</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cardiac Glycosides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

